Rare condition

Metabolic disease due to other fatty acid oxidation disorder

00

studies recruiting now

checking live

00

studies registered in total

checking live

00

countries with a recruiting site

checking live

00

recruiting study posted to date

checking live

Recruiting trials

Fetching live from ClinicalTrials.gov. This condition is not yet in our weekly snapshot; live results only.

Keep watching

Get an email when a new Metabolic disease due to other fatty acid oxidation disorder study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

A group of conditions, not a single diagnosis

Orphanet classifies “Metabolic disease due to other fatty acid oxidation disorder” as a category that groups several related conditions. Trials are usually registered under the specific condition, so the figures above may undercount. Browse the conditions in this group or see the classification on Orphanet.

Treatments being studied

6 approved treatments and 17 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Saxagliptin (Saxagliptin component of qternmet)Approved: Velaglucerase Alfa (Vpriv)Approved: Taliglucerase Alfa (Elelyso)Approved: Dapagliflozin (Dapagliflozin component of br1019)Approved: Alendronate Sodium (Alendronate sodium)Approved: Eliglustat Tartrate (Cerdelga)
Phase 3Rosiglitazone (Avandia)
Phase 3Metformin
Phase 3Ramipril (Altace)
Phase 3Trelagliptin Succinate
Phase 3Stannsoporfin
Phase 3Trelagliptin
Phase 3Fenofibrate (Antara)
Phase 2Afegostat Tartrate

+ 9 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).